眼科医疗

Search documents
人老眼先衰,老花矫正手术热度攀升,哪些眼科公司能抢占老龄红利?
Cai Jing Wang· 2025-09-19 08:28
Core Viewpoint - The aging population in China is driving the demand for presbyopia correction technologies, which include optical correction, surgical correction, and drug treatment. The industry is witnessing rapid development, with both public and private healthcare institutions expanding their services in this area [1][3][4]. Industry Overview - The prevalence of presbyopia treatment methods in China is currently low, indicating that the market is still in its early stages, presenting significant growth potential [3][5]. - The aging population is expected to reach over 400 million by 2035, with more than 40% of the population being elderly by mid-century, leading to an increase in age-related eye diseases [3][4]. Company Developments - 德视佳 reported a 2.8% increase in revenue from presbyopia treatments, reaching 121.4 million HKD in the first half of 2025, while revenue from Presbyond treatment rose from 1.2 million HKD in 2024 to 3.6 million HKD [2][6]. - 爱尔眼科 achieved a revenue of 11.507 billion CNY in the first half of 2025, a 9.12% year-on-year increase, with a net profit of 2.051 billion CNY, reflecting a 0.05% growth [6][7]. - 爱尔眼科 is actively promoting awareness and education regarding presbyopia treatments, anticipating significant market growth driven by the increasing payment capacity and quality demands of the aging population [6][7]. Market Dynamics - The demand for presbyopia treatments is expected to continue rising, with the three-focus lens replacement surgery being identified as the most effective method for addressing this condition [7]. - Despite a decline in net profit for 德视佳 in the first half of 2025, the company remains optimistic about the presbyopia treatment market, viewing it as a key growth driver even in challenging economic conditions [7].
上海爱尔清亮眼科医院违规收费被罚 爱尔眼科参股
Zhong Guo Jing Ji Wang· 2025-09-19 06:14
天眼查工商信息显示,上海爱尔清亮眼科医院有限公司,成立于2019年,位于上海市,是一家以从事卫 生为主的企业。企业注册资本3500万人民币,实缴资本2450万人民币。 其股东信息显示,湖南亮视视界医疗产业管理合伙企业(有限合伙)持股70%,为第一大股东。爱尔眼科 (300015)医院集团股份有限公司(简称"爱尔眼科",300015.SZ)直接持股0.2857%,间接持股比例 13.65%。 中国经济网北京9月19日讯信网17日报道《上海爱尔清亮眼科医院因违规收费被罚》显示,上海爱尔清 亮眼科医院有限公司因存在重复收费和分解项目收费的违规行为,被上海市青浦区医疗保障局处罚。 行政处罚决定书(青医保罚决字第2220250122号)显示,上海爱尔清亮眼科医院有限公司因在医疗服务中 存在重复收费和分解项目收费的行为,违反了《医疗保障基金使用监督管理条例》(国务院令第735号) 第三十八条第三项的规定。上海市青浦区医疗保障局依据《医疗保障基金使用监督管理条例》(国务院 令第735号)第三十八条相关规定,对上海爱尔清亮眼科医院有限公司处以34303元罚款。 ...
爱尔眼科:眼科市场空间实际上在逐步扩大
Zheng Quan Shi Bao Wang· 2025-09-19 04:57
人民财讯9月19日电,有投资者在互动平台向爱尔眼科(300015)提问:从2021年到现在四年时间公司 业绩停滞不前,公司未来的增长点在哪里?爱尔眼科回复,经济环境和外部因素对眼科行业有一定影 响,但透过浮沫看潜流,眼科市场空间实际上在逐步扩大。一方面,眼疾病及视力损伤患者群体基数庞 大,目前各亚专科诊疗渗透率偏低。另一方面,近视人群居高不下,人口老龄化程度持续加深,白内 障、老视、干眼症等年龄相关性眼病持续增长。公司加快业务创新,促进各学科全面发展,推动诊疗量 不断增长。 ...
破发股华厦眼科跌2.95% 2022年上市超募19.9亿元
Zhong Guo Jing Ji Wang· 2025-09-18 09:13
Core Viewpoint - Huaxia Eye Hospital's stock price has declined significantly since its IPO, currently trading at 20.72 yuan, representing a drop of 2.95% and indicating a state of underperformance since its initial offering price of 50.88 yuan [1] Group 1: IPO and Financial Performance - Huaxia Eye Hospital was listed on the Shenzhen Stock Exchange's ChiNext board on November 7, 2022, with an initial offering price of 50.88 yuan per share [1] - The total funds raised from the IPO amounted to 305.28 million yuan, with a net amount of 276.85 million yuan after deducting issuance costs [1] - The final amount raised exceeded the original plan by 198.99 million yuan, which was initially set at 77.85 million yuan for various projects [1] Group 2: Use of Proceeds - The funds raised are intended for several projects, including the Tianjin Huaxia Eye Hospital project, regional vision center construction, upgrading existing medical service capabilities, information management system development, and supplementing operational funds [1] Group 3: Dividend Distribution - On July 4, 2023, Huaxia Eye Hospital announced a cash dividend of 2.8 yuan per 10 shares, totaling 15.68 million yuan, based on a total share capital of 56 million shares as of December 31, 2022 [2] - Additionally, the company will increase its share capital by 5 shares for every 10 shares held, raising the total share capital from 56 million to 84 million shares [2]
何氏眼科:公司参与产业投资基金的设立是为了寻找优质的投资标的
Zheng Quan Ri Bao Zhi Sheng· 2025-09-17 14:13
证券日报网讯 何氏眼科9月17日在互动平台回答投资者提问时表示,公司前期投资参与产业投资基金的 设立,主要是基于战略聚焦、专业分工,是为了围绕公司眼健康主业,在上下游产业链及相关新一代医 疗健康新兴领域寻找优质的投资标的。 (编辑 姚尧) ...
何氏眼科:公司是一家由“专家办院”,集医、教、研于一体眼健康服务机构
Zheng Quan Ri Bao Zhi Sheng· 2025-09-17 14:13
(编辑 姚尧) 证券日报网讯 何氏眼科9月17日在互动平台回答投资者提问时表示,公司是一家由"专家办院",集医、 教、研于一体眼健康服务机构,创立以来秉承"贡献社会 患者信赖 共同发展"的经营理念,为大众提供 全生命周期的眼健康服务。公司深耕眼健康领域二十余年,拥有丰富的眼健康服务经验、成熟的医师培 养体系、良好的患者口碑及完善的三级眼健康医疗服务模式,以打造"智慧光明城"为目标,通过精准医 疗和智慧医疗赋能,为患者全面开启数字化、全场景、全生命周期眼健康管理的服务新模式,为患者提 供精准、便捷的眼科健康管理,推动眼科医疗服务向智能化、个性化的方向发展。 ...
爱尔眼科荣登“中国慈善榜”
Huan Qiu Wang· 2025-09-16 11:18
Group 1 - The core viewpoint of the article highlights the significant contributions of Aier Eye Hospital Group in charitable donations and its commitment to rural health initiatives, ranking 19th among 1182 companies in the 2025 China Charity List with a total donation of 21.672 million yuan [1] - Aier Eye Hospital integrates support for rural revitalization into its development strategy, aiming for equal access to medical services between urban and rural areas, and has established a leadership group to facilitate this initiative [3] - The company has developed a comprehensive eye health charity support mechanism targeting low-income families, focusing on preventing poverty caused by illness through various outreach programs [5] Group 2 - Aier Eye Hospital has implemented a three-tiered public health service system for eye health, enhancing the capabilities of rural medical institutions and personnel through its "graded chain" model [5][6] - The company has invested in digital ophthalmology technology to improve accessibility and affordability of eye care services, including equipping township health centers with AI imaging devices and providing remote consultation services [6] - Aier Eye Hospital has supported 873 public welfare projects across 31 provinces, helping over 1.5 million patients regain their sight and training more than 6000 rural doctors [6]
华厦眼科:接受惠璞投资调研
Mei Ri Jing Ji Xin Wen· 2025-09-16 10:14
Company Overview - Huaxia Eye Hospital (SZ 301267) announced an investor research meeting scheduled for September 16, 2025, where the company’s board secretary and securities representatives will address investor inquiries [1] Financial Performance - For the first half of 2025, Huaxia Eye Hospital's revenue composition is as follows: Refractive services account for 36.9%, comprehensive optometry projects for 24.04%, cataract services for 20.14%, posterior segment projects for 12.94%, and other services for 5.99% [1] - As of the report date, Huaxia Eye Hospital has a market capitalization of 17.9 billion yuan [1]
研报掘金丨国海证券:维持爱尔眼科“买入”评级,探索开发眼科医疗数据和“AI+眼科”
Ge Long Hui A P P· 2025-09-16 07:26
Core Viewpoint - The report from Guohai Securities indicates a slight increase in net profit for the first half of 2025, with a focus on the company's growth in outpatient and surgical volumes, as well as advancements in AI technology within the ophthalmology sector [1] Financial Performance - The company's net profit attributable to shareholders for 1H2025 is 2.051 billion yuan, reflecting a growth of 0.05% [1] - The net profit excluding non-recurring items is 2.040 billion yuan, showing a significant increase of 14.30% [1] Operational Metrics - In 1H2025, the company achieved an outpatient volume of 9.25 million visits, which is an increase of 16.47% [1] - The number of surgeries performed reached 879,000, marking a growth of 7.63% [1] Changes in Reporting Standards - Starting from 2025, the reporting standard for corneal laser surgeries has changed from "one case per person" to "one case per eye," leading to retrospective adjustments in the previous year's surgical volume data [1] Growth Areas - The refractive and optometry segments are experiencing rapid growth, while cataract procedures are dragging down overall growth rates [1] - The company's overseas medical service network is continuously improving, contributing to a faster growth in foreign income [1] Technological Advancements - The company is developing and enhancing the "AI Smart Ophthalmology Hospital," which aims to improve AI-assisted diagnostic capabilities and has introduced the "AI Ophthalmologist" intelligent system [1] Competitive Position - The company is recognized as a global leader in the ophthalmology medical group, with a deepening domestic and international service network and medical innovation capabilities that create a long-term competitive advantage [1] - The investment rating is maintained at "Buy" [1]
辽宁何氏眼科医院集团股份有限公司 2025年第一次临时股东大会决议公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-09-16 02:18
登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:301103 证券简称:何氏眼科 公告编号:2025-032 辽宁何氏眼科医院集团股份有限公司 1.会议召开方式:本次股东大会采用现场和网络投票相结合的方式召开。 2.会议召开日期和时间: 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假记载、误导性陈述或重大遗 漏。 重要提示: 1.本次股东大会无增加、变更、否决提案的情况。 2.本次股东大会以现场与网络投票相结合的方式召开。 一、会议召开和出席情况 辽宁何氏眼科医院集团股份有限公司(以下简称"公司")2025年第一次临时股东大会于2025年9月15日 召开,公司董事会已于2025年8月28日在巨潮资讯网上刊登了《关于召开2025年第一次临时股东大会的 通知》。 本次股东大会由公司董事会召集,现场会议由公司董事周晋峰先生主持,会议召开符合《公司法》《上 市公司股东大会规则》《深圳证券交易所创业板股票上市规则》及《公司章程》等规定。 现场会议时间为:2025年9月15日(星期一)14:00 网络投票时间为:2025年9月15日(星期一) 其中,通 ...